A PRAGMATIC CLINICAL STUDY OF NEOADJUVANT CHEMOTHERAPY FOLLOWED BY SURGERY VERSUS SURGERY ALONE FOR PATIENTS WITH HIGH RISK RETROPERITONEAL SARCOMA

Informations projet

STREXIT2

N° de convention de subvention: 101103843

DOI

10.3030/101103843

Date de signature de la CE 21 Avril 2023

Date de début 1 Juin 2023

Date de fin 31 Mai 2028

Financé au titre de

• Health

Coût total

€ 4 971 875,00

Contribution de l’UE

€ 4 971 875,00

Coordonné par

ORGANISATION EUROPEENNE POUR LA RECHERCHE ET LE TRAITEMENT DU CANCER AISBL
Belgium

Periodic Reporting for period 2 - STREXIT2 (A PRAGMATIC CLINICAL STUDY OF NEOADJUVANT CHEMOTHERAPY FOLLOWED BY SURGERY VERSUS SURGERY ALONE FOR PATIENTS WITH HIGH RISK RETROPERITONEAL SARCOMA)

Période du rapport: 2024-06-01 au 2025-11-30

Résumé du contexte et des objectifs généraux du projet

Retroperitoneal sarcomas are rare diseases refractory to treatment with dismal prognosis. Surgery is the only standard approach to primary disease. We are proposing an innovative pragmatic approach supplementing a standard phase III clinical trial with an observational cohort. It is proposed to amend the ongoing phase III EORTC clinical trial STRASS2 investigating the added value of neoadjuvant chemotherapy before surgery for high-risk retroperitoneal sarcoma and to add an observational arm STREXIT2 that will capture real world data from patients not participating to STRASS2. We will compare the clinical outcomes between STRASS2 and STREXIT2 and explore the possible combination of STRASS2 and matched STREXIT2 patients to strengthen the results of the randomized clinical trial data and increase the power of subgroup analyses. If conclusive, the proposed research will help to understand the clinical added value and costs-effectiveness of neoadjuvant chemotherapy before surgery for high-risk retroperitoneal sarcoma. We will perform health economics analysis assessing the economic value of different treatment scenarios based on STRASS2 and STREXIT2. If successful, the outcomes of the project will define a new evidence-based standard of care for high-risk retroperitoneal sarcomas. The proposed research could lead to improved patient survival and quality of life but also improving health system sustainability. This is a multidisciplinary and multistakeholder consortium involving clinical oncologists, surgeons, health economists and patient representatives. The study design was successfully discussed with patients

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

The first patient was recruited on 4th June 2024 in the STREXIT2 arm of the clinical trial STRASS2. We are experiencing a delay in recruitment since 165 patients were recruited in STREXIT2 as of end of November 2025 instead of the expected double number of patients. This is still a remarkable achievement given the rarity of the disease. As a matter of facts, we have included in STREXIT2 as many patients as in STRASS2, already doubling the number of patients available for analysis. We stimulated the participating clinical sites to recruit patients faster. In addition, the study protocol was amended to allow the enrolment of deceased patients which should help as well, since for some time this was not possible and many of the retrospective patients had in fact died. On the health economics side, as it was planned, the activities have been ongoing since project start. Finally, regarding communication and dissemination, we published one scientific article, project newsletters and we posted on social media. The project website is updated.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

It is too early. The project clinical trial has not yet delivered any result.

strexit-assets-logo-color.png